Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ocular Therapeutix (OCUL) Tops Q3 EPS by 2c
November 12, 2019 7:03 AM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.45), $0.02 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $829 thousand versus the consensus estimate of $580 thousand.
We have had very productive quarter, said Antony Mattessich, President and Chief Executive... More
